In this report, we have demonstrated that Wnt-2 protein is overexpressed in freshly resected human non-small-cell lung cancer (NSCLC) tissues. We have also developed a monoclonal antibody against the N-terminus of human Wnt-2 protein. This monoclonal antibody induces apoptosis in human NSCLC cell lines that overexpress Wnt-2 protein. Incubation of this antibody with normal human airway cells lacking Wnt-2 expression does not induce apoptosis. Wnt-2 signaling blockade by the anti-Wnt-2 antibody is confirmed by downregulation of cytosolic bcatenin and reduction in TCF-dependent transcriptional activity (TOPFLASH assay). In addition, Wnt-2-specific small interfering RNA (siRNA) treatment in the NSCLC cell line A549 also downregulated cytosolic b-catenin and induced apoptosis. Moreover, downregulation of an inhibitor of apoptosis family protein, Survivin, was noticed both in the Wnt-2 antibody-and siRNA-treated NSCLC cells, suggesting that inhibition of Wnt-2-mediated signaling induces apoptosis through inactivating Survinin.
Lung cancer is the leading cause of cancer deaths in the US and worldwide, with 4170 000 newly diagnosed cases each year in the US and nearly million cases worldwide (Minna et al., 2002; Jemal et al., 2004) . Despite progresses made in the past decades, the 5-year survival rate for lung cancer remains under 15% (Minna et al., 2002; Jemal et al., 2004) . Lung cancers are divided into two main groups: non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). NSCLC (80% of all lung cancers) consists of three major types: adenocarcinoma, squamous cell carcinoma, and largecell carcinoma (Minna et al., 2002) . Lung adenocarcinomas and squamous cell carcinomas represent 60-70% of all lung cancers. Surgery, radiation, and chemotherapy have been used with generally unsatisfactory results in advanced lung cancers. A better understanding of molecular mechanisms for lung cancer pathogenesis may offer more targets for the therapeutics of patients with lung cancer.
Wnt ligand binds directly to the cysteine-rich extracellular domain of Frizzled (Fz), and this binding activates canonical and/or noncanonical pathways (Hsieh et al., 1999; Dann et al., 2001) . The activation of canonical pathway leads to signal transduction through Dishevelled (Dvl) and results in b-catenin stabilization and accumulation in the cytoplasm. The cytoplasmic b-catenin translocates into the nucleus and binds to Tcf/Lef transcription factors to make a heterodimeric complex that activates the transcription of Wnt target genes, for example, c-myc and cyclin D1 (He et al., 1998; Tetsu and McCormick, 1999; Uthoff et al., 2001; Wodarz and Nusse, 1998) . Wnt/b-catenin signaling promotes cell survival in various cell types (Orford et al., 1999; Reya et al., 2000; Satoh et al., 2000; Shih et al., 2000; Chen et al., 2001; Ioannidis et al., 2001) . For instance, it has been shown that a dominant negative form of Tcf-4 was able to block Wnt-mediated survival and cells were sensitized to apoptosis (Chen et al., 2001) . Noncanonical pathways are referred as Wnt signaling pathways that signal independently of bcatenin (Veeman et al., 2003) . The role of Wnt signaling in cancer was suggested by the discovery of Wnt-1 as an integration site of MMTV in mouse mammary carcinoma (Nusse and Varmus, 1982) . Overexpression of Wnt (e.g. Wnt-1, Wnt-2) that signals through b-catenin promotes transformation of mouse mammary epithelial cell line C57MG cells (Blasband et al., 1992; Shimizu et al., 1997) . Increasing evidence suggests that the Wnt signaling pathway is involved in tumor development and/or progression (Bienz and Clevers, 2000; Peifer and Polakis, 2000; Polakis, 2000; You et al., 2002) . Mutations in b-catenin, APC, and Axin have been found in human colon cancers, suggesting that constitutive activation of Wnt canonical pathway contributes to human carcinogenesis (Uthoff et al., 2001) . Wnt-2 has been implicated in human carcinogenesis by upregulation (Huguet et al., 1994; Dale et al., 1996; Vider et al., 1996; Smith et al., 1999) . For instance, frequent upregulation of Wnt-2 has been reported in human colorectal cancer and gastric cancer (Katoh, 2001) . Moreover, Holcombe et al. (2002) recently analysed the expression of specific Wnt genes in human colon cancer and malignant melanoma by in situ hybridization and their results suggest that Wnt-2 overexpression may be involved in human carcinogenesis (Pham et al., 2003) .
To test our hypothesis that Wnt-2 overexpression may be involved in human lung carcinogenesis, we first studied Wnt-2 protein expression in matched human normal lung and NSCLC tissues using a commercially available anti-Wnt-2 antibody raised against a peptide mapping near the amino terminus of Wnt-2 of human origin (Santa Cruz Biotechnology, Santa Cruz, CA, USA), and we found that seven out of eight freshly resected NSCLC tissues had increased expression of Wnt-2 protein compared with autologous-matched normal lung tissue controls ( Figure 1a ). These eight NSCLC fresh tumors (four squamous cell and four adenocarcinomas) and their autologous-matched normal lung tissues were obtained from patients undergoing resection of their tumors as part of their treatment for early-stage I NSCLC (IRB approval H8714-15319-04). Patients had not received any prior treatment (i.e. radiation, chemotherapy, etc.). Then, we had a monoclonal antibody against a N-terminal peptide of human Wnt-2 custom made by Rockland, Inc. (Gilbertsville, PA, USA). The peptide sequence was bioinformatically searched to ensure its speicificy to Wnt-2. We performed immunoprecipitation with this monoclonal antibody alone or after preincubation with blocking peptide (30-fold over the antibody) in cell extracts from C57Wnt-2 cell line and a NSCLC cell line A549 (Figure 1b ). Wnt-2 protein from both cell lines was precipitated by the monoclonal anti-Wnt-2 antibody. When the monoclonal anti-Wnt-2 antibody was preincubated with blocking peptide, its ability to precipitate Wnt-2 protein was blocked in both cell lines. Wnt-2 protein was not precipitated by the monoclonal antibody after preincubating with the blocking peptide. These data indicate that the anti-Wnt-2 monoclonal antibody can bind specifically to the native form of Wnt-2 protein. Wnt-2 protein expression was found in four human NSCLC cell lines: A549, H1299, H1703, and H460 ( Figure 1c ). Wnt-2 expression was not observed in the small airway epithelial cells (SAEC), and normal primary human bronchial epithelial cells (NHBE) were used as normal controls.
Next, we used the anti-Wnt-2 monoclonal antibody to treat four human NSCLC cell lines: A549, H1299, H1703, and H460. After 3-5 days of incubation, we found significant cell death in all these cell lines (over 90% cell death at 10 mg/ml of the antibody, Po0.005) (Figure 2a ). We saw no noticeable cytopathic effect in these cell lines when the monoclonal antibody was preincubated with blocking peptide or after control monoclonal antibody treatment. Also, no effect was noticed in the NHBE cells treated with the same antibody. Cell killing was due largely to induction of apoptosis (43.6-79.2% of apoptotic cells after 72 h of incubation) ( Figure 2b ). As a specificity control, we examined induction of apoptosis by using monoclonal antibody blocked by overnight preincubation with blocking peptide (30-fold over the antibody) in A549 cells (Figure 2c ). After 72 h of incubation, we found that the anti-Wnt-2 antibody induced apoptosis could be inhibited significantly by blocking peptide (Po0.003). Same dose-blocking peptide (300 mg/ml for 72 h) alone had no effect on cell viability. After about 72 h of treatment with either the monoclonal antibody alone (10.0 mg/ml) or with the monoclonal antibody blocked by preincubation with blocking peptide (30-fold over the antibody), no significant apoptosis induction was detected.
In this study, we found that the cytosolic b-catenin was downregulated after monoclonal anti-Wnt-2 antibody treatment in NSCLC cell line A549 (Figure 3a) . In A549 cells in which the monoclonal anti-Wnt-2 antibody induced apoptosis, we found that the cleaved (active) form of caspase-3 was upregulated. Consistent with this caspase-3 activity, we detected increased levels of cytochrome c in these cells after monoclonal anti-Wnt-2 Immunoprecipitation of Wnt-2 protein in cell lines with the antiWnt-2 monoclonal antibody. Seize X mammalian Immunoprecipitation Kit (Pierce Biotechnology, Rockford, IL, USA) was used to precipitate Wnt-2 protein from cell lysate according to the manufacturer's protocol. C57Wnt-2 served as a positive control. Lanes 1 and 2, monoclonal antibody alone and monoclonal antibody blocked by preincubation with blocking peptide (30-fold over the antibody) with C57Wnt-2 cell lysate; lanes 3 and 4, monoclonal antibody alone and monoclonal antibody blocked by preincubation with blocking peptide with A549 cell lysate. The position of Wnt-2 protein is indicated by an arrow at 34 kDa. (c). Western analysis of Wnt-2 expression in four NSCLC cell lines (A549, H1703, H460, and H1299) and normal cells SAEC and NHBE from Clonetics (Walkersville, MD, USA). Whole-cell lysates were isolated from each cell type. Protein G purified antiWnt-2 mouse monoclonal antibody custom-made at Rockland, Inc. (Gilbertsville, PA, USA) was used to hybridize to the Western blots Wnt-2 blockade induces apoptosis in human lung cancer cells L You et al antibody treatment. In addition, we found that an inhibitor of apoptosis (IAP) protein, Survivin, was also downregulated in these cells after the antibody treatment. In addition, we found significant reduction in TCF-dependent transcriptional activity (TOPFLASH assay) (Po0.01) in the A549 cells after the monoclonal anti-Wnt-2 antibody treatment (Figure 3b) .
Small interfering RNA (siRNA) was carried out by following the protocol described by Elbashir et al. (2002) and Wnt-2-targeted small interfering RNA (siRNA) was used to study the effect of Wnt-2 mRNA silencing. Similar to the monoclonal anti-Wnt-2 antibody, treatment with Wnt-2 siRNA for 3-5 days induced apoptosis in these NSCLC cell lines expressing Wnt-2. Significant apoptosis was induced by 100 nM Wnt-2 siRNA, and no apoptosis was induced by nonsilencicing siRNA control (100 nM) (Po0.01) (Figure 4a) . We confirmed the silencing of Wnt-2 expression after Wnt-2 siRNA treatments (100 nM for 72 h) by Western blot analysis (Figure 4b ). Nonsilencing siRNA served as control (100 nM for 72 h). To determine whether the apoptotic effects correlated with the inhibition of Wnt-2 signaling, we have shown that expression levels of cytosolic b-catenin, and Survivin were downregulated after Wnt-2 siRNA treatment (Figure 4b) .
In this study, we have shown that human NSCLC cell lines overexpress the Wnt-2 protein. The apoptotic cell death induced by either anti-Wnt-2 antibody or Wnt-2 siRNA not only correlates with Wnt-2 expression, but is also accompanied by inhibition of canonical Wnt signaling as evidenced by a decrease in the cytosolic bcatenin levels in the NSCLC cells tested. To elucidate further the possible mechanism(s) through which antiWnt-2 monoclonal antibodies induce apoptosis in human cancer cells, we examined other possible components in the apoptotic pathway. For instance, cytochrome c activates indirectly caspase-3 and IAP(s) mediate inhibition of several caspases including caspase-3 (Chai et al., 2000; Srinivasula et al., 2000) . We observed increased levels of cytochrome c in the cytosol of cancer cells after anti-Wnt-2 antibody treatment. Our results indicate that both caspase-3 and cytochrome c are most likely involved in this anti-Wnt-2 antibodyinduced apoptosis through removal of Survivin and/or other IAPs-mediated inhibition as well as direct caspases activation, respectively. Our findings suggest that the Wnt-2 blockade may also likely also partially reverse chemotherapy-induced drug resistance. Thus, Wnt-2 upregulation may function as a survival mechanism by inhibiting normal apoptotic machinery in these tumor cells. Survivin is overexpressed in most human cancers and its interaction with mitotic spindle is essential for antiapoptotic function (Li et al., 1998) . Our data is consistent with the recent findings that Survivin is a target gene of b-catenin/Tcf-4 in colorectal cancer Kim et al., 2003) . Two groups have shown similar results that Tcf-binding sites were identified in the promoter region of the Survivin gene and a dominant negative form of TCF was able to block Survivin gene expression Kim et al., 2003) . Previously, it has been shown that antisense to Survivin induces apoptosis and potentiates chemotherapy in the NSCLC cell line A549 (Olie et al., 2000) . Inhibition of Wnt-2 signaling may, theoretically, synergize with and potentiates the effect of cytotoxic chemotherapy in these human NSCLC cells. In summary, our results indicate that Wnt-2 blockade by either monoclonal antibody or siRNA induces apoptosis in some human NSCLC cells and that Wnt-2 may be a target for the treatment of NSCLC. These data suggest that the anti-Wnt-2 antibody and siRNA can induce specifically selective apoptosis in NSCLC cells through inhibition of Wnt pathway(s). Therefore, the anti-Wnt-2 monoclonal antibody and Wnt-2 siRNA may be useful as therapeutic strategies for the treatment of lung cancer. . Anti-b-catenin antibody was purchased from Transduction Laboratories (Lexington, KY, USA). Anti-cytochrome c antibody was from BD Biosciences (San Diego, CA, USA). For detecting alteration of b-catenin and cytochrome c, cytosolic extracts were prepared and examined as described previously (Wang et al., 1999) . (b) TOPFLASH assay of Tcfdependent transcriptional activity in NSCLC cell line A549. Cells were plated in six-well plates. After incubation with control or antiWnt-2 monoclonal antibody (10 mg/ml) for 48 h, the TOPFLASH or FOPFLASH reporter plasmid was transfected transiently into cells as described previously (Uematsu et al., 2003) . Tcf-mediated gene transcription was determined by the ratio of pTOPFLASH : p-FOPFLASH luciferase activity, each was normilized to luciferase activities of the pRL-TK reporter (cotransfected internal control). The results are means 7s.d. (error bars). All experiments were performed in triplicate. Statistical comparisons were made with a two-sided Student's t-test (Po0.01) Figure 4 Wnt-2 siRNA induces apoptosis and blocks Wnt signal transduction in NSCLC cell line A549. Cells were plated into a sixwell plate with fresh media without antibiotics 24 h before testing. The ion-exchange HPLC-purified siRNAs (Wnt-2 siRNA and nonsilencing siRNA control, 497% pure) were purchased from Qiagen-Xeragon (Germantown, MD, USA). We followed the protocol described by Tuschl's group (Elbashir et al., 2002) . After siRNA transfection, plates were incubated for 3-5 days at 371C before further analysis. (a) Annexin V analysis of apoptosis induced by WNT-2 siRNA. From left to right, A549 was treated with 100 nM of nonsilencicing control siRNA, and 100 nM of WNT-2 siRNA, respectively. Cells in necrotic or late apoptotic stages were labeled with both Annexin V-FITC and propidium iodide. (b) Western analysis of WNT-2, b-catenin, Survivin in A549 cells after WNT-2 siRNA treatments (100 nM for 72 h), nonsilencing siRNA served as control. b-Actin served as a loading control Wnt-2 blockade induces apoptosis in human lung cancer cells L You et al
